These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 18615121)
1. Risk for immune-mediated liver reactions by nevirapine revisited. Medrano J; Barreiro P; Tuma P; Vispo E; Labarga P; Blanco F; Soriano V AIDS Rev; 2008; 10(2):110-5. PubMed ID: 18615121 [TBL] [Abstract][Full Text] [Related]
2. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752 [TBL] [Abstract][Full Text] [Related]
4. Third-trimester maternal toxicity with nevirapine use in pregnancy. Joy S; Poi M; Hughes L; Brady MT; Koletar SL; Para MF; Fan-Havard P Obstet Gynecol; 2005 Nov; 106(5 Pt 1):1032-8. PubMed ID: 16260522 [TBL] [Abstract][Full Text] [Related]
5. New nevirapine label underscores the risk for hepatotoxicity in key populations. AIDS Clin Care; 2004 Mar; 16(3):24. PubMed ID: 15119295 [No Abstract] [Full Text] [Related]
6. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials. Ena J; Leach A; Nguyen P HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856 [TBL] [Abstract][Full Text] [Related]
10. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]
11. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
12. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468 [TBL] [Abstract][Full Text] [Related]
13. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR; Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328 [TBL] [Abstract][Full Text] [Related]
14. Initiating therapy: when to start, what to use. Hirsch MS J Infect Dis; 2008 May; 197 Suppl 3():S252-60. PubMed ID: 18447611 [TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for fulminant hepatitis related to nevirapine therapy. Buyse S; Vibert E; Sebagh M; Antonini T; Ichai P; Castaing D; Samuel D; Duclos-Vallée JC Liver Transpl; 2006 Dec; 12(12):1880-2. PubMed ID: 17133571 [TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan. Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984 [TBL] [Abstract][Full Text] [Related]
18. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B; Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689 [TBL] [Abstract][Full Text] [Related]
19. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? Cuzin L; Allavena C; Morlat P; Dellamonica P AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976 [TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. De Lazzari E; León A; Arnaiz JA; Martinez E; Knobel H; Negredo E; Clotet B; Montaner J; Storfer S; Asenjo MA; Mallolas J; Miró JM; Gatell JM HIV Med; 2008 Apr; 9(4):221-6. PubMed ID: 18366445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]